Literature DB >> 18488193

Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.

Craig D Fisher1, Jonathan P Jackson, Andrew J Lickteig, Lisa M Augustine, Nathan J Cherrington.   

Abstract

Non-alcoholic steatohepatitis (NASH) is a disease that compromises hepatic function and the capacity to metabolize numerous drugs. Aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), pregnane X receptor (PXR), peroxisome proliferator-activated receptor alpha (PPARalpha), and nuclear factor-E2 related factor 2 (Nrf2) are xenobiotic activated transcription factors that regulate induction of a number of drug metabolizing enzymes (DMEs). The purpose of the current study was to determine whether experimental NASH alters the xenobiotic activation of these transcription factors and induction of downstream DME targets Cyp1A1, Cyp2B10, Cyp3A11, Cyp4A14 and NAD(P)H:quinone oxidoreductase 1 (Nqo1), respectively. Mice fed normal rodent chow or methionine-choline-deficient (MCD) diet for 8 weeks were then treated with microsomal enzyme inducers beta-naphoflavone (BNF), 1,4-bis-[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), pregnenolone-16alpha-carbonitrile (PCN), clofibrate (CFB) or oltipraz (OPZ), known activators of AhR, CAR, PXR, PPARalpha and Nrf2, respectively. Results of this study show that (1) Hepatic PXR mRNA levels were significantly increased (1.4-fold) in mice fed MCD diet, while AhR, CAR, PPARalpha and Nrf2 were not affected. (2) The MCD diet did not alter hepatic inducibility of Cyp1A1, Cyp2B10, Cyp3A11 mRNA levels by their respective microsomal inducers. (3) Constitutive levels of Cyp4A14 mRNA were significantly increased in mice fed the MCD diet, yet further induction by clofibrate was not observed. (4) Hepatic Nqo1 mRNA levels were significantly increased by the MCD diet; however, additional induction of Nqo1 was still achievable following treatment with the Nrf2 activator OPZ.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18488193      PMCID: PMC4294556          DOI: 10.1007/s00204-008-0312-z

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  29 in total

1.  The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes.

Authors:  M McMahon; K Itoh; M Yamamoto; S A Chanas; C J Henderson; L I McLellan; C R Wolf; C Cavin; J D Hayes
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

2.  Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene.

Authors:  R Venugopal; A K Jaiswal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 3.  Etiopathogenesis of nonalcoholic steatohepatitis.

Authors:  S Chitturi; G C Farrell
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

4.  Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2.

Authors:  Craig D Fisher; Lisa M Augustine; Jonathan M Maher; David M Nelson; Angela L Slitt; Curtis D Klaassen; Lois D Lehman-McKeeman; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2007-03-12       Impact factor: 3.922

Review 5.  CAR, the continuously advancing receptor, in drug metabolism and disease.

Authors:  M Qatanani; D D Moore
Journal:  Curr Drug Metab       Date:  2005-08       Impact factor: 3.731

Review 6.  Regulation of hepatic transporters by xenobiotic receptors.

Authors:  C D Klaassen; A L Slitt
Journal:  Curr Drug Metab       Date:  2005-08       Impact factor: 3.731

7.  Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Authors:  Li-Qun Yang; Shen-Jing Li; Yun-Fei Cao; Xiao-Bo Man; Wei-Feng Yu; Hong-Yang Wang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 8.  The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.

Authors:  S Harmsen; I Meijerman; J H Beijnen; J H M Schellens
Journal:  Cancer Treat Rev       Date:  2007-04-23       Impact factor: 12.111

9.  Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis.

Authors:  Andrew J Lickteig; Craig D Fisher; Lisa M Augustine; Nathan J Cherrington
Journal:  J Biochem Mol Toxicol       Date:  2007       Impact factor: 3.642

Review 10.  PPARalpha in atherosclerosis and inflammation.

Authors:  Fokko Zandbergen; Jorge Plutzky
Journal:  Biochim Biophys Acta       Date:  2007-05-21
View more
  21 in total

1.  Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.

Authors:  Rohitash Jamwal; Suzanne M de la Monte; Ken Ogasawara; Sravani Adusumalli; Benjamin B Barlock; Fatemeh Akhlaghi
Journal:  Mol Pharm       Date:  2018-06-11       Impact factor: 4.939

2.  Interstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism.

Authors:  Volodymyr Tryndyak; Aline de Conti; Tetyana Kobets; Kristy Kutanzi; Igor Koturbash; Tao Han; James C Fuscoe; John R Latendresse; Stepan Melnyk; Svitlana Shymonyak; Leonard Collins; Sharon A Ross; Ivan Rusyn; Frederick A Beland; Igor P Pogribny
Journal:  FASEB J       Date:  2012-08-07       Impact factor: 5.191

Review 3.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

4.  Editor's Highlight: Neonatal Activation of the Xenobiotic-Sensors PXR and CAR Results in Acute and Persistent Down-regulation of PPARα-Signaling in Mouse Liver.

Authors:  Cindy Yanfei Li; Sunny Lihua Cheng; Theo K Bammler; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2016-07-13       Impact factor: 4.849

Review 5.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 6.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

7.  Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-01-02       Impact factor: 3.922

8.  In Vivo Exposures to Particulate Matter Collected from Saudi Arabia or Nickel Chloride Display Similar Dysregulation of Metabolic Syndrome Genes.

Authors:  Jason Brocato; Michelle Hernandez; Freda Laulicht; Hong Sun; Magdy Shamy; Mansour A Alghamdi; Mamdouh I Khoder; Thomas Kluz; Lung-Chi Chen; Max Costa
Journal:  J Toxicol Environ Health A       Date:  2015

Review 9.  Nuclear receptors and nonalcoholic fatty liver disease.

Authors:  Matthew C Cave; Heather B Clair; Josiah E Hardesty; K Cameron Falkner; Wenke Feng; Barbara J Clark; Jennifer Sidey; Hongxue Shi; Bashar A Aqel; Craig J McClain; Russell A Prough
Journal:  Biochim Biophys Acta       Date:  2016-03-04

Review 10.  Pathogenesis of alcoholic liver disease: the role of nuclear receptors.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.